Soltis Investment Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Soltis Investment Advisors’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,190	Closed	-$216K	–	246
2021 Q2	$216K	Buy	+2,190	New	+$191K	0.03%	228
2021 Q1	–	Sell	-2,747	Closed	-$237K	–	217
2020 Q4	$237K	Buy	+2,747	New	+$213K	0.04%	197

Other funds holding BIB

HCM

Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

OPS

Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UMC

United Maritime Capital New York $15.2M AUM 45.42% 1-Year Est. Return

Soltis Investment Advisors's BIB Position: Q3 2021 in Review

Soltis Investment Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2021, closing a stake of 2,190 shares — an estimated $216K sold.

Soltis Investment Advisors first reported a position in BIB in Q4 2020 and held it in 2 quarters. The position peaked at $237K in Q4 2020. 32 funds tracked by Wall St. Rank hold BIB as of Q3 2021.

Soltis Investment Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2021 after selling out during the quarter.
Soltis Investment Advisors sold 2,190 ProShares Ultra NASDAQ Biotechnology shares in Q3 2021, an estimated $216K.
Soltis Investment Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2020 and held it in 2 quarters.
Soltis Investment Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $237K in Q4 2020.
32 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2021.

Based on Soltis Investment Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.